Drug Information

Drug (ID: DG01825) and It's Reported Resistant Information

• Name: Morphine
• Synonyms: Morphine; Morphia; Morphium; Morphinum; Morphin; (-)-Morphine; Morphina; Ospalivina; DepoDur; 57-27-2; Duromorph; Meconium; Morphinism; Moscontin; MS Contin; l-Morphine; Dulcontin; Morfina; Nepenthe; Roxanol; MORPHINE SULFATE; Infumorph; Dreamer; Morpho; Avinza; Hocus; Kadian; Unkie; Cube juice; Hard stuff; Statex SR; Ms Emma; Morphin [German]; Morfina [Italian]; Duramorph; Morphina [Italian]; M-Eslon; Morphine [BAN]; CCRIS 5762; HSDB 2134; Anhydrous morphine; (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol; UNII-76I7G6D29C; CHEBI:17303; CHEMBL70; (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol; 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol; (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL; Morphine Anhydrate; 76I7G6D29C; Morphine (BAN); Dolcontin; RMS; (5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-; (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol; methyl[ ]diol; Aguettant; Dinamorf; Sevredol; Dimorf; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; D-(-)-Morphine; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-; EINECS 200-320-2; Oramorph; DEA No. 9300; (Morphine); Morphine anhydrous; N02AA01; Morphine polistirex; Substitol (TN); MOR; (-)-(etorphine); (-)Morphine sulfate; Morphine (anhydrous); Morfina Dosa (TN); NSC11441; Morphine extended release; Epitope ID:116646; SCHEMBL2997; BIDD:GT0147; GTPL1627; IDS-NM-009; DTXSID9023336; Morphine 0.1 mg/ml in Methanol; Morphine 1.0 mg/ml in Methanol; ZINC3812983; BDBM50000092; AKOS015966554; DB00295; MOI; C01516; D08233; Hydromorphone hydrochloride impurity, morphine-; Q81225; 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; UNII-1M5VY6ITRT component BQJCRHHNABKAKU-KBQPJGBKSA-N; 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol; 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol(morphine); (5alpha,6beta)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; 3-(4-Hydroxy-phenyl)-1-propyl-piperidine-3-carboxylic acid ethyl ester; 6-tert-Butyl-3-methyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine; (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-; Morphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; (1S,5R,13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraene-10,14-diol; (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18),15-tetraene-10,14-diol; (morphine) 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 2-{4-[2,4-diamino-6-pteridinylmethyl(methyl)amino]phenylcarboxamido}pentanedioic acid(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ; HydroChloride; 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ;sulphate salt(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol((Morphine)); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine sulfate); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine)(HCl); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol,sulfate(Morphinesulfate); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diolMorphine; 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol (morphine); 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine); 6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol(Morphine); 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-; MORPHINE; (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL; MORPHIUM; MORPHIA; DOLCONTIN; DUROMORPH; MORPHINA; NEPENTHE; Morphine;4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
• Indication:
  In total 1 Indication(s)
  Chronic pain [ICD-11: MG30]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (2 diseases)
  Ischemia/reperfusion injury [ICD-11: DB98]; [2]
  Neurodegeneration [ICD-11: 8A07]; [1]
• Target: Opioid receptor mu (MOP); OPRM_HUMAN; [1]
• IsoSMILES: CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O
• InChI: InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
• InChIKey: BQJCRHHNABKAKU-KBQPJGBKSA-N
• PubChem CID: 5288826
• ChEBI ID: CHEBI:17303
• TTD Drug ID: D0WE3O
• VARIDT ID: DR1112
• INTEDE ID: DR00467
• DrugBank ID: DB00295

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-08: Nervous system diseases

Neurodegeneration [ICD-11: 8A07]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Mitochondrially encoded cytochrome c oxidase II (MT-CO2) [1]

• Molecule Alteration: Up-regulation; Expression
• Resistant Disease: Morphine mediated neurodegeneration [ICD-11: 8A07.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: A172 cells; Brain; Homo sapiens (Human); CVCL_0131
• In Vitro Model: Human primary astrocytes; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: BV-2 microglial cells; Brain; Mus musculus (Mouse); CVCL_0182
• In Vivo Model: C57BL/6N WT mice model; Tlr7-/- mice model; Pregnant WT mice model; Mus musculus
• Experiment for Molecule Alteration: Knockdown assay
• Experiment for Drug Resistance: Phagocytosis assay; Flow cytometry assay
• Mechanism Description: Astrocyte EV-Induced lincRNA-Cox2 Regulates Microglial Phagocytosis: Implications for Morphine-Mediated Neurodegeneration.

ICD-13: Digestive system diseases

Ischemia/reperfusion injury [ICD-11: DB98]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: TINCR ubiquitin domain containing (TINCR) [2]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Ischemia/reperfusion injury [ICD-11: DB98.B]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: H9C2 cells; Ovary; Cricetulus griseus (Chinese hamster); CVCL_A0TS
• In Vivo Model: Rat model of I/R injury; Rattus norvegicus
• Experiment for Molecule Alteration: RIP experiments assay; RNA pull down assay; qRT-PCR; Western bloting analysis; Knockdown assay; Overexpression assay
• Experiment for Drug Resistance: CCK8 assay; TUNEL assay; Flow cytometry assay
• Mechanism Description: MpostC-induced upregulation of TINCR protects cardiomyocytes from I/R injury via inhibiting degradation and ubiquitination of FGF1, and subsequently activating PKCepsilon signaling pathway, which provides a novel insight in the mechanism of TINCR and PKCepsilon during MpostC treatment of I/R injury.

References

• Ref 1: Astrocyte EV-Induced lincRNA-Cox2 Regulates Microglial Phagocytosis: Implications for Morphine-Mediated NeurodegenerationMol Ther Nucleic Acids. 2018 Dec 7;13:450-463. doi: 10.1016/j.omtn.2018.09.019. Epub 2018 Sep 29.
• Ref 2: Morphine post-conditioning-induced up-regulation of lncRNA TINCR protects cardiomyocytes from ischemia-reperfusion injury via inhibiting degradation and ubiquitination of FGF1QJM. 2020 Dec 1;113(12):859-869. doi: 10.1093/qjmed/hcaa088.